00

Zhejiang Anglikang Pharmaceutical Co Ltd Class A

002940 · SHE · Healthcare / Drug Manufacturers - Specialty & Generic

23.51CNY-1.06 (-4.31%)

Price History

Full chart

Market Stats

Previous Close24.57
Open24.70
Day Range23.34 – 24.95
52-Week Range22.22 – 48.52
Volume10.33M
Market Cap4.63B
P/E (TTM)41.00
Forward P/E0.00
EPS0.56
Dividend Yield1.63%
Beta0.71
50-Day Avg24.95
200-Day Avg30.69

About

Zhejiang AngLiKang Pharmaceutical CO.,LTD. engages in the research, development, production, and sale of pharmaceuticals in China and internationally. The company offers chemical raw materials for pharmaceuticals comprising oral cephalosporin antibiotic raw materials, including cephalexin, cefadroxil, cefaclor, and cefadroxil; alpha-keto acid raw materials; inhaled anesthetic raw materials, such as isoflurane and sevoflurane; and anti-androgen intermediates, including finasteride and dutasteride. It also provides chemical agents consisting of anti-infective preparations, such as cefixime and cefadroxil capsules, cefaclor sustained-release tablets, cefaclor granules, and cefalexin capsules; cardiovascular preparations, including levamlodipine besylate and amlodipine besylate tablets, nifedipine sustained-release and sacubitril/valsartan sodium tablets, and measartan potassium and ticagrelor tablets; anesthetic and analgesic preparations, such as sevoflurane inhalation, liprocaine cream, and pregabalin capsules; nephropathy preparations, including compound a-keto acid tablets, levocarnitine oral solutions, and lanthanum carbonate chewable tablets; oryzanol and doxofylline tablets; and other products. In addition, the company offers specialty intermediates, such as plant-derived cholesterol and its derivatives, plant-derived vitamin D3, and plant-derived 25-hydroxyvitamin D3. Further, it provides lyophilized powder injections, steroidal biological products, and plant extracts; penicillin; and active pharmaceutical ingredients (APIs) for respiratory system, digestive system, and pain indications. Additionally, the company engages in biotechnology promotion activities. The company serves pharmaceutical companies, commercial and pharmaceutical distribution companies, chemical and nutritional companies, and feed companies. Zhejiang AngLiKang Pharmaceutical CO.,LTD. was founded in 2001 and is headquartered in Shengzhou, China.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Guo Gang Zheng
  • Employees1.24K
  • HeadquartersNo. 1000, North Shengzhou Avenue, Shengzhou, China, 312400, China
  • Websitehttps://www.alkpharm.com

Leadership

  • Mr. Guo Gang ZhengGM & Director · b. 1973
  • Mr. Huihao LuDeputy GM & Vice Chairman of the Board · b. 1970

Financials

Income Statement

Currency: CNY2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue681.51M773.79M671.58M873.15M1.26B1.40B1.29B1.38B1.57B1.62B1.51B1.42B
Growth (%)-+13.54%-13.21%+30.01%+43.74%+11.25%-7.63%+7.04%+13.62%+3.32%-6.63%-5.84%
Cost of Revenue525.92M597.25M456.01M409.59M380.44M378.02M321.24M488.02M674.86M913.72M925.32M862.36M
Gross Profit155.59M176.54M215.57M463.56M874.61M1.02B968.41M892.36M893.58M706.85M587.78M562.45M
Gross Margin22.83%22.82%32.10%53.09%69.69%72.92%75.09%64.65%56.97%43.62%38.85%39.48%
Operating Expense105.87M115.51M126.25M339.85M743.37M863.07M756.73M718.19M745.02M495.17M427.35M359.36M
Operating Income49.72M61.03M89.33M123.72M131.24M155.10M211.68M174.17M148.56M211.68M160.44M203.09M
Operating Margin7.30%7.89%13.30%14.17%10.46%11.11%16.41%12.62%9.47%13.06%10.60%14.25%
EBITDA95.52M109.73M133.80M160.35M165.45M176.28M203.65M197.60M202.87M241.03M205.30M270.34M
EBITDA Margin14.02%14.18%19.92%18.36%13.18%12.63%15.79%14.32%12.93%14.87%13.57%18.97%
Net Income50.13M64.03M82.19M101.09M108.70M112.27M163.72M119.84M127.30M138.37M80.33M125.44M
Net Income Margin7.36%8.27%12.24%11.58%8.66%8.04%12.69%8.68%8.12%8.54%5.31%8.80%
R&D36.63M40.63M46.84M40.97M46.21M37.35M43.88M52.55M112.62M143.37M214.34M144.05M
R&D as % of Total Revenue5.37%5.25%6.97%4.69%3.68%2.67%3.40%3.81%7.18%8.85%14.17%10.11%
Interest Expense10.25M16.68M9.31M5.72M2.56M768.52K689.87K730.83K6.79M14.72M17.10M13.00M
Interest Expense % of Total Revenue1.50%2.16%1.39%0.65%0.20%0.06%0.05%0.05%0.43%0.91%1.13%0.91%

Balance Sheet

Currency: CNY2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets731.44M799.83M727.99M906.78M1.47B1.38B1.94B2.08B2.60B3.02B2.97B2.95B
Total Liabilities514.36M535.63M400.56M512.41M499.27M368.51M562.78M608.64M949.93M1.19B1.18B1.08B
Total Equity180.49M247.47M310.85M370.19M919.07M965.13M1.32B1.34B1.50B1.59B1.53B1.63B
Cash39.99M30.42M59.74M139.48M618.33M527.70M854.07M688.91M735.47M859.75M697.38M687.41M
Total Debt219.23M189.80M113.33M80.00M15.00M69.83M10.01M98.14M345.20M557.09M465.11M-
Net Debt179.23M159.38M53.59M-59.48M-603.33M-457.86M-844.06M-590.77M-390.26M-271.99M-232.27M-

Cash Flow

Currency: CNY2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow50.46M138.59M141.74M193.77M133.61M213.49M198.61M197.65M184.75M276.91M253.60M244.13M
Investing Cash Flow-50.33M-79.82M12.33M-44.08M-69.09M-228.79M20.66M-232.80M-521.32M-178.50M-461.91M-
Financing Cash Flow-9.92M-60.14M-133.57M-80.25M397.71M-97.34M177.41M-123.60M376.62M21.23M-313.44M-
Capital Expenditure48.48M35.10M25.81M54.79M68.17M75.58M90.96M87.32M68.82M124.95M94.46M49.94M
Free Cash Flow1.98M103.49M115.93M138.99M65.44M137.91M107.65M110.33M115.92M151.96M159.14M194.19M
Dividends Paid75.07M21.59M29.07M45.20M1.93M67.50M90.00M46.94M28.17M61.62M58.77M57.60M
FCF to OCF3.93%74.67%81.79%71.73%48.98%64.60%54.20%55.82%62.75%54.88%62.75%79.54%
Dividend Paid to FCF3786.61%20.87%25.07%32.52%2.94%48.95%83.61%42.55%24.30%40.55%36.93%29.66%

Earnings

Report DateMar 31, 2019Jun 30, 2019Sep 30, 2019Mar 30, 2020Apr 21, 2020Jul 28, 2020Oct 27, 2020Feb 26, 2021Apr 29, 2021Aug 20, 2021Oct 28, 2021Feb 25, 2022Mar 31, 2022Jun 30, 2022Sep 30, 2022Mar 31, 2023Apr 28, 2023Aug 25, 2023Oct 27, 2023Feb 28, 2024Apr 26, 2024Jun 30, 2024Oct 29, 2024Dec 31, 2024Apr 25, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate------------------------------
EPS Actual0.180.170.130.170.320.340.300.300.230.240.070.350.200.200.150.140.230.280.030.140.140.20-0.090.150.080.260.060.240.090.19
Surprise------------------------------
Timing---After-hoursPre-marketPre-marketPre-marketAfter-hoursPre-marketAfter-hoursPre-marketPre-market---After-hoursPre-marketAfter-hoursPre-marketAfter-hoursPre-market-Pre-market-After-hours-----

Key Statistics & Ratios

Market Cap4.63B
Enterprise Value4.27B
Trailing P/E41.00
Forward P/E0.00
Price / Sales3.49
Price / Book2.84
EPS0.56
Book Value8.44
Revenue (TTM)1.33B
Gross Profit (TTM)522.81M
EBITDA193.68M
Profit Margin8.62%
Operating Margin11.80%
Return on Equity7.59%
Return on Assets2.46%
Shares Outstanding201.73M
Shares Float98.52M
Beta0.71
Dividend Yield1.63%
Dividend Rate0.38
Payout Ratio42.84%

Dividends

20261×
0.15Jun 22, 2026
20252×
0.10Nov 24, 20250.13Jul 7, 2025
20241×
0.21Jun 17, 2024
20231×
0.30May 19, 2023
20221×
0.14Jun 20, 2022
20211×
0.24Jul 6, 2021
20201×
0.48Jun 23, 2020
20191×
0.36May 21, 2019

Stock Splits

  • May 19, 20231.45:1
  • Nov 15, 20221.45:1